Eric H. Bernicker, MD

Professor of Clinical Oncology, Academic Institute
Full Clinical Member, Research Institute
Diane Harkins Modesett Professor of Medical Oncology, Houston Methodist
Weill Cornell Medical College


Biography

Dr. Bernicker earned his medical degree from Baylor College of Medicine in Houston, TX in 1990. Subsequently, he completed his residency at Baylor Affiliated Hospitals and was chief medical resident at Ben Taub General Hospital from 1993–1994. Dr. Bernicker held a faculty appointment at Baylor College of Medicine as a clinical assistant professor from 1996–2012 before joining the Houston Methodist Cancer Center in January 2013, where he serves as director of Medical Thoracic Oncology. As a physician-scientist, Dr. Bernicker oversees the expansion of clinical trials at The Methodist Hospital relating to Thoracic Oncology with all stages of disease, a combination of SWOG trials, and industry trials of novel targeted agents. 

Description of Research

Dr. Bernicker’s research focuses on looking at different therapeutic approaches, such as targeted therapies and immunotherapies, in the treatment of lung cancer. By understanding how to identify patients at risk for relapse after surgery or those who can be spared the toxicities of chemotherapy, the immune system can be stimulated to preferentially destroy tumor cells, spare normal tissues, and improve patient survival along with the development of less toxic therapeutics. Eventually, the goal is to be able to offer new therapies and clinical trials to patients at Methodist with any stage of non-small cell lung cancer or small cell lung cancer.

Areas Of Expertise

Lung cancer Cancer research Targeted therapeutics
Education & Training

MD, Baylor College of Medicine
Residency, Baylor College of Medicine
Clinical Fellowship, Baylor College of Medicine
Internship, Dallas County Hospital -Parkland Memorial Hospital
Publications

Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
Lei, X, Zhu, S, Ren, D, Ren, F, Li, T, Zhou, N, Li, S, Shi, T, Zu, L, Song, Z, Chalubinska-Fendler, J, Denis, MG, Bernicker, EH, de Montpréville, VT, Jiang, R & Xu, S 2022, , Translational Lung Cancer Research, vol. 11, no. 6, pp. 1176-1184. https://doi.org/10.21037/tlcr-22-394

Three-year outcomes of uveal melanoma treated with intra-operative ultrasound-guided iodine-125 brachytherapy using custom-built eye plaques
Wong, AJ, Teh, BS, Nguyen, BT, Pino, R, Bretana, ME, Bernicker, EH, Chevez-Barrios, P, Butler, EB & Schefler, AC 2022, , Journal of Contemporary Brachytherapy, vol. 14, no. 2, pp. 130-139. https://doi.org/10.5114/jcb.2022.115379

Contemporary trends in management of uveal melanoma
Chevli, N, Zuhour, RJ, Messer, JA, Haque, W, Schefler, AC, Bernicker, EH, Chevez-Barrios, P, Farach, AM, Butler, EB & Teh, BS 2022, , Journal of Contemporary Brachytherapy, vol. 14, no. 2, pp. 123-129. https://doi.org/10.5114/jcb.2022.115210

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
Hsu, J, Annunziata, JF, Burns, E, Bernicker, EH, Olsen, RJ & Thomas, JS 2022, , Clinical Pathology, vol. 15. https://doi.org/10.1177/2632010X221102054

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer
Chung, AW, Anand, K, Anselme, AC, Chan, AA, Gupta, N, Venta, LA, Schwartz, MR, Qian, W, Xu, Y, Zhang, L, Kuhn, J, Patel, T, Rodriguez, AA, Belcheva, A, Darcourt, J, Ensor, J, Bernicker, E, Pan, PY, Chen, SH, Lee, DJ, Niravath, PA & Chang, JC 2021, , Science translational medicine, vol. 13, no. 624, abj5070. https://doi.org/10.1126/scitranslmed.abj5070

Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: Retrospective real world data
Allen, TC, Xiao, Y, Yang, B, Croix, D, Abraham, A, Redpath, S, Engstrom-Melynk, J, Shah, R, Madala, J & Bernicker, EH 2021, , Oncotarget, vol. 12, no. 23, pp. 2308-2315. https://doi.org/10.18632/ONCOTARGET.28114

Understanding Factors Associated With Anaplastic Lymphoma Kinase Testing Delays in Patients With Non-Small Cell Lung Cancer in a Large Real-World Oncology Database
Bernicker, EH, Xiao, Y, Croix, DA, Yang, B, Abraham, A, Redpath, S, Engstrom-Melnyk, J, Shah, R & Allen, TC 2021, , Archives of pathology & laboratory medicine. https://doi.org/10.5858/arpa.2021-0029-OA

Time Interval to Initiation of Whole-Brain Radiation Therapy in Patients With Small Cell Lung Cancer With Brain Metastasis
Chevli, N, Hunt, A, Haque, W, Farach, AM, Messer, JA, Sukpraprut-Braaten, S, Bernicker, EH, Zhang, J, Butler, EB & Teh, BS 2021, , Advances in Radiation Oncology, vol. 6, no. 6, 100783. https://doi.org/10.1016/j.adro.2021.100783

DMSA-SPECT: A Novel Approach to Nephron Sparing SBRT for Renal Cell Carcinoma
Chevli, N, Chiang, S, Farach, AM, Haque, W, Satkunasivam, R, Bernicker, EH, Pino, R, Butler, EB & Teh, BS 2021, , Advances in Radiation Oncology, vol. 6, no. 6, 100719. https://doi.org/10.1016/j.adro.2021.100719, https://doi.org/10.1016/j.adro.2021.100719

DMSA-SPECT: A Novel Approach to Nephron Sparing SBRT for Renal Cell Carcinoma
Chevli, N, Chiang, S, Farach, AM, Haque, W, Satkunasivam, R, Bernicker, EH, Pino, R, Butler, EB & Teh, BS 2021, , Advances in Radiation Oncology, vol. 6, no. 6, 100719. https://doi.org/10.1016/j.adro.2021.100719

Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: A single institution experience
Burns, EA, Ensor, JE, Hsu, J, Thomas, JS, Olsen, RJ & Bernicker, EH 2021, , Journal of Thoracic Disease, vol. 13, no. 8, pp. 4785-4796. https://doi.org/10.21037/jtd-21-432

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
Grivas, P, Khaki, AR, Wise-Draper, TM, French, B, Hennessy, C, Hsu, CY, Shyr, Y, Li, X, Choueiri, TK, Painter, CA, Peters, S, Rini, BI, Thompson, MA, Mishra, S, Rivera, DR, Acoba, JD, Abidi, MZ, Bakouny, Z, Bashir, B, Bekaii-Saab, T, Berg, S, Bernicker, EH, Bilen, MA, Bindal, P, Bishnoi, R, Bouganim, N, Bowles, DW, Cabal, A, Caimi, PF, Chism, DD, Crowell, J, Curran, C, Desai, A, Dixon, B, Doroshow, DB, Durbin, EB, Elkrief, A, Farmakiotis, D, Fazio, A, Fecher, LA, Flora, DB, Friese, CR, Fu, J, Gadgeel, SM, Galsky, MD, Gill, DM, Glover, MJ, Goyal, S, Grover, P, Gulati, S, Gupta, S, Halabi, S, Halfdanarson, TR, Halmos, B, Hausrath, DJ, Hawley, JE, Hsu, E, Huynh-Le, M, Hwang, C, Jani, C, Jayaraj, A, Johnson, DB, Kasi, A, Khan, H, Koshkin, VS, Kuderer, NM, Kwon, DH, Lammers, PE, Li, A, Loaiza-Bonilla, A, Low, CA, Lustberg, MB, Lyman, GH, McKay, RR, McNair, C, Menon, H, Mesa, RA, Mico, V, Mundt, D, Nagaraj, G, Nakasone, ES, Nakayama, J, Nizam, A, Nock, NL, Park, C, Patel, JM, Patel, KG, Peddi, P, Pennell, NA, Piper-Vallillo, AJ, Puc, M, Ravindranathan, D, Reeves, ME, Reuben, DY, Rosenstein, L, Rosovsky, RP, Rubinstein, SM, Salazar, M, Schmidt, AL, Schwartz, GK, Shah, MR, Shah, SA, Shah, C, Shaya, JA, Singh, SRK, Smits, M, Stockerl-Goldstein, KE, Stover, DG, Streckfuss, M, Subbiah, S, Tachiki, L, Tadesse, E, Thakkar, A, Tucker, MD, Verma, AK, Vinh, DC, Weiss, M, Wu, JT, Wulff-Burchfield, E, Xie, Z, Yu, PP, Zhang, T, Zhou, AY, Zhu, H, Zubiri, L, Shah, DP, Warner, JL & Lopes, GL 2021, , Annals of Oncology, vol. 32, no. 6, pp. 787-800. https://doi.org/10.1016/j.annonc.2021.02.024

Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib
Li, J, Zhang, B, Zhang, Y, Xu, F, Zhang, Z, Shao, L, Yan, C, Ulivi, P, Denis, MG, Christopoulos, P, de Montpréville, VT, Bernicker, EH, van der Wekken, AJ, Wang, C & Yue, D 2021, , Translational Lung Cancer Research, vol. 10, no. 3, pp. 1525-1535. https://doi.org/10.21037/tlcr-21-160

Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers
Bernicker, EH, Xiao, Y, Abraham, A, Yang, B, Croix, DA, Redpath, S, Engstrom-Melnyk, J, Shah, R, Madala, J & Allen, TC 2021, , Oncologist, vol. 26, no. 6, pp. e1050-e1057. https://doi.org/10.1002/onco.13779

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance
The COVID-19 and Cancer Consortium 2020, , Cancer Cell, vol. 38, no. 6, pp. 761-766. https://doi.org/10.1016/j.ccell.2020.10.022

Understanding the associations between smoking-related risk perception, interest in quitting smoking, and interest in lung cancer screening among homeless adult smokers
Agrawal, P, Taing, M, Chen, TA, Reuven, SM, Businelle, MS, Kendzor, DE, Bernicker, EH & Reitzel, LR 2020, , International journal of environmental research and public health, vol. 17, no. 23, 8817, pp. 1-11. https://doi.org/10.3390/ijerph17238817

Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma
Anand, K, Phung, TL, Bernicker, EH, Cagle, PT, Olsen, RJ & Thomas, JS 2020, , Clinical Lung Cancer, vol. 21, no. 5, pp. 437-442. https://doi.org/10.1016/j.cllc.2020.05.007

Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database
Messer, JA, Zuhour, RJ, Haque, W, Lewis, GD, Schefler, AC, Wong, A, Bernicker, EH, Chevez-Barrios, P, Michelle Quan, E, Farach, A, Butler, EB, Hatch, SS & Teh, BS 2020, , Journal of Contemporary Brachytherapy, vol. 12, no. 4, pp. 303-310. https://doi.org/10.5114/jcb.2020.98108

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
COVID-19 and Cancer Consortium 2020, , The Lancet, vol. 395, no. 10241, pp. 1907-1918. https://doi.org/10.1016/S0140-6736(20)31187-9

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
Kasparian, S, Gentille, C, Burns, E & Bernicker, EH 2020, , JTO Clinical and Research Reports, vol. 1, no. 2, 100017. https://doi.org/10.1016/j.jtocrr.2020.100017